Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × zipalertinib × 90 days × Clear all

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Diseases 1 Carcinoma 1

Interventions

Specimen Handling 228 pembrolizumab 203 Magnetic Resonance Spectroscopy 187 Biopsy 139 Carboplatin 138 Cyclophosphamide 117 Nivolumab 113 Cisplatin 110 Paclitaxel 102 Radiotherapy 89 Gemcitabine 74 Bevacizumab 72 venetoclax 67 durvalumab 67 Dexamethasone 65 Oxaliplatin 60 Rituximab 58 Docetaxel 57 Ipilimumab 56 Fluorouracil 56 atezolizumab 55 Prednisone 54 Capecitabine 54 fludarabine 53 Etoposide 51 olaparib 49 Radiation 49 Drug Therapy 49 Doxorubicin 48 Cytarabine 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05967689 2026-03-10

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡